Compare ISSC & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ISSC | FHTX |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.6M | 332.2M |
| IPO Year | 2000 | 2020 |
| Metric | ISSC | FHTX |
|---|---|---|
| Price | $27.64 | $4.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $16.50 | $11.50 |
| AVG Volume (30 Days) | ★ 624.8K | 126.7K |
| Earning Date | 05-26-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | 25.32 |
| EPS | ★ 0.22 | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | $6.63 | $14.62 |
| Revenue Next Year | $8.13 | $15.27 |
| P/E Ratio | $126.95 | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $5.30 | $2.94 |
| 52 Week High | $30.98 | $6.95 |
| Indicator | ISSC | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.75 | 35.07 |
| Support Level | $17.57 | $4.44 |
| Resistance Level | N/A | $5.85 |
| Average True Range (ATR) | 2.11 | 0.37 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 58.53 | 15.75 |
Innovative Solutions and Support Inc is a systems integrator that designs, manufactures, sells, and services air data equipment, engine display systems, standby equipment, primary flight guidance, and cockpit display systems for retrofit applications and original equipment manufacturers. The company supplies integrated Flight Management Systems, Flat Panel Display Systems, Integrated Standby Units, Positioning System receivers that enable reduced carbon footprint navigation, and an Autothrottle, which allows a pilot to automatically control the power setting of the engine and is designed to reduce pilot workload and enhance safety. It sells its products to both the OEM and the retrofit markets.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.